Roche’s Genentech unit is emphasizing next-generation breast cancer therapies, targeted oncology combinations and brain-penetrating treatments at ASCO 2026.
Key Investor Takeaways
- Genentech, part of Roche Group (USOTC:RHHBY), will present new oncology data across nine approved and investigational medicines at the 2026 ASCO Annual Meeting.
- New clinical data for giredestrant could support its emergence as a future standard endocrine therapy in ER-positive breast cancer.
- The company will present additional studies involving HER2-positive breast cancer, KRAS-mutated lung cancer and diffuse large B-cell lymphoma.
- Investors may focus on upcoming regulatory developments tied to giredestrant, including ongoing FDA review activity.
- The ASCO presentations reinforce Genentech’s strategy around targeted therapies, antibody-drug conjugates and precision oncology platforms.
Why RHHBY Stock Is In Focus
Genentech, a member of Roche Group (USOTC:RHHBY), announced that it will present new oncology data spanning more than 15 cancer indications during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 29 through June 2 in Chicago.
The company said its presentations will include data from nine approved and investigational medicines across breast cancer, lung cancer, blood cancers and other oncology programs.
A major focus of the ASCO presentation slate will be giredestrant, an investigational oral selective estrogen receptor degrader (SERD) being studied in estrogen receptor-positive, HER2-negative breast cancer.
According to Genentech, this subtype represents approximately 70% of all breast cancer cases, with most diagnoses occurring at the early stage.
“Genentech’s ASCO data reflect our commitment to addressing those cancers that impose the highest burden on patients and society,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “In particular, our ASCO data highlight significant advances in breast cancer, including the latest results for giredestrant and our evolving approach to HER2-positive metastatic disease.”
Giredestrant data remains central focus
Genentech said updated data from three Phase III studies will be presented at ASCO.
lidERA Breast Cancer study
The company said new data from the lidERA study will evaluate whether giredestrant maintains consistent efficacy and safety across both pre-menopausal and post-menopausal patients with early breast cancer.
The company previously reported a 30% reduction in the risk of invasive disease recurrence or death in December 2025 and confirmed that the lidERA data package has already been submitted to the FDA.
persevERA Breast Cancer study
Primary data from the persevERA study will examine giredestrant in combination with palbociclib as a first-line therapy for locally advanced or metastatic disease.
Genentech noted that while the study did not meet its primary endpoint, the treatment combination demonstrated a numerical progression-free survival improvement in endocrine-sensitive disease.
evERA Breast Cancer study
The company will also present post-progression treatment analyses from the evERA trial involving giredestrant plus everolimus in patients previously treated with CDK4/6 inhibitors.
Genentech noted that the FDA recently accepted the New Drug Application for giredestrant based on positive evERA results.
HER2-positive and precision oncology pipeline also highlighted
Genentech additionally plans to present early data involving RG6596/ZN-A-1041, a brain-penetrating HER2-selective tyrosine kinase inhibitor designed to improve treatment of HER2-positive metastatic breast cancer and brain metastases.
Beyond breast cancer, the company will showcase precision oncology programs including:
- Divarasib combined with pembrolizumab in KRAS G12C-positive non-small cell lung cancer
- Lunsumio plus Polivy in relapsed or refractory diffuse large B-cell lymphoma
The company said the Lunsumio and Polivy combination could potentially provide chemotherapy-free treatment options for transplant-ineligible lymphoma patients.
Why This Matters For Investors
The ASCO presentations may matter to investors because they provide important clinical and regulatory updates across several of Roche and Genentech’s major oncology growth programs.
Giredestrant in particular represents a potentially important future revenue driver in hormone receptor-positive breast cancer, especially as the company positions the therapy across multiple treatment settings.
Investors may also view the broader ASCO lineup as evidence of Genentech’s continued emphasis on targeted therapies, bispecific antibodies, antibody-drug conjugates and precision medicine approaches designed to address difficult-to-treat cancers.
At the same time, several programs remain investigational, and future commercial success will depend on additional clinical data, regulatory approvals and competitive positioning against other oncology therapies already on the market or in development.
What To Watch Next
Investors will likely monitor:
- Detailed ASCO 2026 clinical data presentations
- FDA review progress for giredestrant
- Further progression-free survival and recurrence data from ongoing breast cancer studies
- Development of HER2-positive brain metastasis therapies
- Phase III progress for divarasib in KRAS-mutated lung cancer
- Commercial potential for chemotherapy-free lymphoma combinations
- Additional oncology pipeline updates from Roche and Genentech